Acorda Therapeutics Stock Price and Value Analysis

Should you buy Acorda Therapeutics stock? (NasdaqGS:ACOR). Let's see how it does in our automated value investing analysis system.

ACOR Free Cash Flow Trend

Free Cash Flow trendline for ACOR
Free Cash Flow trendline for Acorda Therapeutics

Hmm, we can't give any reliable projection for Acorda Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This company is not making money.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the ACOR Numbers

ACOR Price
(Acorda Therapeutics stock price per share)
[?] PE Ratio versus Sector 26% lower than other Healthcare stocks
[?] PE Ratio versus Industry 74% lower than other Biotechnology stocks
[?] Cash Yield 34.97%
[?] Free Cash Flow Jitter 372%

Is Acorda Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Acorda Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ACOR Stock?

Does Acorda Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.